Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors in Clinical Practice: A Focused Update | Zendy

Evan A. Stein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors in Clinical Practice: A Focused Update

Author(s) -

Evan A. Stein

Publication year - 2017

Publication title -

us cardiology review

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.148

H-Index - 3

eISSN - 1758-390X

pISSN - 1758-3896

DOI - 10.15420/usc.2017:23:1

Subject(s) - kexin , proprotein convertase , pcsk9 , subtilisin , clinical trial , medicine , proprotein convertases , clinical practice , bioinformatics , pharmacology , cholesterol , ldl receptor , chemistry , biochemistry , biology , lipoprotein , enzyme , family medicine

This article provides an updated review of the LDL-cholesterol efficacy, safety, and cardiovascular benefits of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. It focuses on evidence from numerous clinical trials and provides clinicians with a basis for understanding, assessing, and selecting these agents for clinical practice. It also provides some perspective on other potential agents in development that target PCSK9.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research